リポプロテインリパースの活動は,胸痛の重症度と関連しています. レグレス研究グループ (REGRESS Study Group) は,レグレスについて研究している
J J Kastelein1, J W Jukema, A H Zwinderman
1Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Circulation
|October 4, 2000
まとめ
リポプロテインリパース (LPL) の活性と質量は,心血管疾患の重症度に関連しています. 低LPLレベルは,アンギナとイシュケミアの増加と相関しており,LPLが冠動脈疾患のリスクに影響することを示唆しています.
科学分野:
- 心血管科学 心血管科学
- 脂質代謝についてです.
- 酵素学 酵素学とは
背景:
- トリグリセリドに富んだリポタンパク質の上昇は,心血管疾患の重要なリスク因子です.
- リポプロテインリパース (LPL) の活動は,これらのリポプロテインをクリアするために重要であり,潜在的に心血管リスクを調節します.
研究 の 目的:
- 男性の冠動脈疾患患者のLPL活動と質量,およびイシュケミアの重症度の間の関係を調査する.
- LPL濃度と静脈性心筋梗塞や静音性心筋梗塞などの不血症の臨床指標との関連性を評価する.
主な方法:
- REGRESS試験の男性冠動脈疾患患者のコホートで測定されたLPLのポストヘパリン活性と質量.
- NYHA分類を用いたアンギナ重度の評価と,24時間AMBULATORY ECGモニタリングによるサイレント・イシュケミアの評価.
- LPLレベル,アンギナクラス,および不血症負荷の間の相関を分析した.
主要な成果:
- LPL活動四分数の下位にある患者は,より重度のアンギナを報告した (47%のクラスIII/IV対最高四分数の29%,P=0.002).
- 下のLPLアクティビティクォーティルは,ECGモニタリングでより高い全血栓負荷を示した (36.5+/-104.1 mm x min vs. 14.8+/-38.8 mm x min,P=0.001).
- LPL活動と質量 (r=0.70,P<0.0001) の間には強い相関が見出され,NYHAクラスに関連するLPL質量 (P=0.012).
結論:
- LPLの質量/活動とイシュケミアの重症度 (アンギナクラス,EKG) の間には有意な関係がある.
- LPLは,触媒的および非触媒的メカニズムの両方を通じて冠動脈疾患のリスクに影響を与えるようです.
関連する概念動画
Angina I: Introduction
Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


